TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06236633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Description: Embolization performed via a common right femoral or radial approach, depending on the patient's conformation. Minor complications such as hematoma at the puncture site are rare in less than 1% of cases, and serious complications are exceptional. Proximal occlusion of the inferior mesenteric artery, before its dividing branches, using material adapted to arterial occlusion according to anatomical findings. Proximal occlusion during embolization is evaluated by intravascular injection into the inferior mesenteric artery, and resumption of vascularization of the distal inferior mesenteric artery is controlled by the border arcade injecting into the superior mesenteric artery. In the event of a high-risk anatomical variant, or absence of a border arcade, no embolization will be performed and the patient will be excluded from the study; this will represent no more than 1-2% of patients (surgical series describing 0.83% of ischemia in connection with absence of a border arcade).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriogram
Description: The interventional radiologist performs an arteriogram of the inferior and superior mesenteric arteries (IMA and SMA respectively) to check that the SMA is free of anomalies and that the IMA has a proximal trunk long enough for embolization. The radiologist also checks for the presence of a colonic border arcade. If this is absent, embolization will not be performed: the patient will be excluded from the study.This arteriogram is carried out under local anaesthetic specifically for research purposes, as follows: Common right femoral or radial approach and placement of a small introducer. Selective arteriogram of the inferior and superior mesenteric arteries to check perfusion of the border arcade.Arterial closure system or manual compression. Return to surgery or interventional radiology department. Patient discharged the same day after medical assessment (surgeon or interventional radiologist).Telephone check-up on Day1 (standard management) and Day 7 (added as part of the protocol).
Study: NCT05978700

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: The control group used the conventional swallowing function training. The lip exercise consisted of the following specific movements: opening mouth, closing mouth, drumming cheeks, left drumming cheeks, and right drumming cheeks; the tongue exercise consisted of the following specific movements: extending the tongue, tongue up, tongue down, tongue left, and tongue right. Each specific movement in the steps lasts 2-3s, repeat 15 times and continue with the next movement. The lower jaw movement contains the following specific movements: keep the head as low as possible, and squeeze the rubber ball placed on the neck for 2-3 seconds, repeat 15 times.
Study: NCT05613777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon®
Description: ethinylestradiol (EE) and levonorgestrel (LNG)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: BI 425809
Study: NCT05475275

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreaticojejunostomy
Description: The experimental group underwent intraoperative measurements (A: short distance from the center of the pancreatic duct to the edge of the pancreas) and (B: pancreatic thickness). When the ratio of the thickness of the short distance from the center of the pancreatic duct to the edge of the pancreas at the pancreatic section was ≥0.401, it was divided into the N1 group (central pancreatic duct). If the ratio was \<0.401, it was divided into the N2 group (eccentric pancreatic duct). The central pancreatic duct group was given 1+1 mode pancreaticojejunostomy; the eccentric pancreatic duct group was given 1+1² mode pancreaticojejunostomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreaticojejunostomy
Description: The experimental group underwent intraoperative measurements (A: short distance from the center of the pancreatic duct to the edge of the pancreas) and (B: pancreatic thickness). When the ratio of the thickness of the short distance from the center of the pancreatic duct to the edge of the pancreas at the pancreatic section was ≥0.401, it was divided into the N1 group (central pancreatic duct). If the ratio was \<0.401, it was divided into the N2 group (eccentric pancreatic duct). The central pancreatic duct group was given 1+1 mode pancreaticojejunostomy; the eccentric pancreatic duct group was given 1+1² mode pancreaticojejunostomy.
Study: NCT05395195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Erythropoietin injections (500u/kg) x 9 doses

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Supportive neonatal intensive care
Description: Neonatal intensive care monitoring and support including ventilatory and inotropic support as clinically indicated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive neonatal intensive care
Description: Neonatal intensive care monitoring and support including ventilatory and inotropic support as clinically indicated
Study: NCT06237088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online mindfulness program
Description: The intervention includes an eight-week internet-based mindfulness program. The program introduces participants to a new mindfulness topic every week. These topics are heavily inspired by the eight-week mindfulness programs.
Study: NCT05817799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine 500Mg thrice daily
Description: L-Carnitine 500mg oral thrice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1g L-Carnitine IV three times a week
Description: 1g IV L-Carnitine three times a week
Study: NCT06237088

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: eight-week mindfulness programs
Description: The intervention consists of 2.5-hour classes per week over a period of eight weeks.
Study: NCT05547698

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Off-pump lung transplantation
Description: General anesthesia, intubation with double lumen tube, thoracotomies or clamshell incision, pneumonectomy starting by the less perfused lung in the scan, stump preparation, lung implantation, reperfusion, gradual release of the pulmonary artery clamp, deairing, ventilation of the 1st implanted lung. The process is repeated at the contralateral side. Ventilation of both lungs, chest closure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Venoarterial ECMO lung transplantation
Description: General anesthesia, intubation with double lumen tube, thoracotomies or clamshell incision, heparin, peripheral or central venoarterial ECMO cannulation, first pneumonectomy, stump preparation, lung implantation, reperfusion, release of the pulmonary artery clamp, deairing, ventilation of the 1st implanted lung. The process is repeated at the contralateral side. Ventilation of both lungs, ECMO decannulation, chest closure.
Study: NCT05700968

Intervention type: OTHER
Intervention: validity and reability study
Description: Validity and reliability assessment of the Turkish version of the Multidimensional Outcome Expectations For Exercise Scale (MOEES).
Study: NCT04954326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyophilized S95014
Description: Lyophilized S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.~Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liquid S95014
Description: Liquid S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.~Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol.
Study: NCT05876390

Intervention type: PROCEDURE
Intervention: Breast surgery
Description: Breast surgery

Intervention type: DRUG
Intervention: analgesia
Description: Multimodal analgesia
Study: NCT06263075

Intervention type: PROCEDURE
Intervention: Intraoperative monitoring
Description: ANESTHESIOLOGICAL MANAGEMENT accords to usual practice. Participants underwent preoperative fasting (3 h for breast milk, 4 h for formula milk, and 1 h for clear liquids), no premedication, induction and maintenance by sevoflurane, fentanyl boluses for analgesia, mechanical ventilation (PEEP 4 cm H2O, target tidal volume 6-8 ml/Kg, end tidal CO2 32-40 mmHg), 10 ml/Kg/h of intraoperative fluids. Scalp block is performed before surgery.~MONITORING DURING SURGERY: monitor devices routinely used are connected to the participant: Dräger Infinity Delta XL®, Masimo® for pulse oximetry (Rainbow SET), regional cerebral oximetry (O3TM), and (optional) brain function monitoring (Masimo® SedLine). Arterial blood gas test is sampled at the anesthesiologist's discretion. After the artery catheterization, the MostCare® system is simultaneously connected to the patient monitoring devices. Data are collected every 3 minutes, 6 minutes for the noninvasive blood pressure measurement.
Study: NCT05559151

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remimazolam Benzenesulfonate
Description: In the experimental group, remazolam 6-12mg/kg/h, atracurium cisphenylate 0.1-0.3 mg/kg and sufentanil 0.3-0.5 μg/kg were infused by micropump for anesthesia induction, and the BIS value was controlled at 50±5 before tracheal intubation.~Anesthesia maintenance: intravenous infusion of remifentanil 0.1-0.3 μg/kg/min, target controlled infusion of remifentanil in experimental group (group R), BIS value was controlled at 50±5, intermittent addition of atracurium cisphenylate to maintain muscle relaxation.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Remimazolam Benzenesulfonate
Description: In the experimental group, remazolam 6-12mg/kg/h, atracurium cisphenylate 0.1-0.3 mg/kg and sufentanil 0.3-0.5 μg/kg were infused by micropump for anesthesia induction, and the BIS value was controlled at 50±5 before tracheal intubation.~Anesthesia maintenance: intravenous infusion of remifentanil 0.1-0.3 μg/kg/min, target controlled infusion of remifentanil in experimental group (group R), BIS value was controlled at 50±5, intermittent addition of atracurium cisphenylate to maintain muscle relaxation.
Study: NCT05569213

Intervention type: DIAGNOSTIC_TEST
Intervention: motor evoked potentials
Description: see previous descriptions
Study: NCT05555147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nerve block with 0.5% ropivacaine
Description: After general anesthesia, the patients will receive bilateral infraorbital and infratrochlear nerve block 30 minutes prior to surgery. Infraorbital nerve block is performed while using an extraoral approach. A 25-gauge needle was inserted laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. The index finger of the non-dominant hand was positioned above the infraorbital foramen, and the needle was advanced until it was felt beneath the finger. 2 ml of the 0.5% ropivacaine slowly injected after negative aspiration of blood was confirmed. Inserting the needle 1 cm above the inner canthus, targeting the junction of the orbit and the nasal bone, performed infratrochlear nerve block. After negative aspiration of blood, 1 ml of the 0.5% ropivacaine was injected. Contralateral nerve block was performed in the same manner.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: without any nerve block
Description: Patients receiving general anesthesia without Infraorbital and Infratrochlear nerve block.
Study: NCT05261841

Intervention type: OTHER
Intervention: Standard care for T2D patients, Smartwatch
Description: No intervention, observational study
Study: NCT04917445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spikes-focused bad news protocol
Description: Nurses trained to deliver bad news to IVF patients based on the Spikes-protocol for compassionately delivering bad news to patients.
Study: NCT05203679

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Single dose intravenous injection of BBM-H901
Description: Single dose intravenous infusion of BBM-H901, an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor IX (hFIX) transgene in liver. The dose of BBM-H901 will be 1×10\^13 vg/ kg
Study: NCT05847907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant placement
Description: Implant placement in subject with type 2 diabetes mellitus. Implant placement in subjects with type 2 diabetes mellitus. Implants with BA surface will be placed in one group of subjects and implants with SA surface in the other group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: Implant placement in subject with type 2 diabetes mellitus. Implant placement in subjects with type 2 diabetes mellitus. Implants with BA surface will be placed in one group of subjects and implants with SA surface in the other group.
Study: NCT06341140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding support and Booklet containing information about breastfeeding
Description: Pregnant women in the intervention group were given individual counseling with a wearable breastfeeding model. During postnatal home visits, mothers were given support on breastfeeding, breast problems were addressed, and information was given to support the mother's self-efficacy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Booklet containing information about breastfeeding
Description: Pregnant women in the control group were given only a breastfeeding booklet, breastfeeding status, breast problems and breastfeeding self-efficacy were evaluated during postnatal home visits and telephone interviews, and risky situations were referred to health professionals.
Study: NCT05974670

Intervention type: DEVICE
Intervention: Consumer wearable device
Description: The subjects are required to wear the consumer wearable devices continuously during the whole study period. The device can provided several physiological parameters, including pulse rate, blood oxygen saturation, physical activity, electrocardiogram, and sleep.
Study: NCT06518447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital occlusal splints (CAD/CAM)
Description: Consists of occlusal stabilization intra-oral splints fabricated using a fully digital workflow, involving intraoral scanning, virtual design, and 3D printing to ensure precise fit and comfort.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional occlusal splints
Description: Consists of occlusal stabilization splints fabricated using traditional analog methods, including physical impressions, plaster models, and manual processing with heat-cured acrylic resin to achieve the desired occlusal arrangement.
Study: NCT04895852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS
Description: The self-adhesive gel electrode pad will be placed at the center of DU20 (Baihui), EX-HN3 (Yintang) and both sides of LI4 (Hegu), LR3 (Taichong) in strict accordance with the World Health Organization Standardized Acupuncture Location. Electric stimulation will be used with a TEAS apparatus (HANS200A Beijing Huawei Co., LTD.) . The frequency of the electrical stimulation will be set as alternating 2/100Hz to relieve anxiety. The current intensity will be adjusted individually, starting at 1 mA and increasing gradually until the patient can perceive and tolerate it (preferably slight twitching of local muscles without pain).
Study: NCT05914064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gravitas FT and Gravitas FT Monitor guidance
Description: FT placed with guidance from the Gravitas FT system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gravitas FT System without placement guidance
Description: SOC placement
Study: NCT05986500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Galactose
Description: The participants will receive a galactose infusion (bolus: 6 mmol, infusion rate: 1 mmol/min)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: The participants will receive a saline infusion
Study: NCT05534724

Intervention type: OTHER
Group type: OTHER
Intervention: Partial weight-bearing (10 - 15kg)
Description: Immediate post-operative partial weight-bearing (10 - 15kg) with a VACOPASO shoe for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complete weight-bearing
Description: Complete post-operative weight-bearing with a VACOPASO shoe for 6 weeks
Study: NCT04895852

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TEAS
Description: The STEAS group selects the same acupoints as the TEAS group and other intervention measures are the same as the TEAS group except for the current intensity is set to 0-mA. The acupuncturist responsible for the operation will tell patients in STEAS group that this is a type of stimulus without perception.
Study: NCT06783127

Intervention type: DRUG
Intervention: Olaparib
Description: Olaparib given according the clinical practice to BRCA positive mCRPC patients
Study: NCT06783374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromodulation
Description: A protocol of posterior tibial nerve electrostimulation will be implemented, inducing retrograde electrostimulation through the pelvic nerves, which are connected to the spinal cord via the sacral plexus at segments S2 and S3. It is recommended to conduct an average of 10 sessions to evaluate the efficacy of the treatment, within a range of 6 to 16 sessions, each lasting 30 minutes, completing a treatment period of 3 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will engage in a 60-minute exercise session, divided into two blocks: Block 1 will comprise 10 to 12 repetitions per set, aiming to achieve a perceived exertion level of 7 to 10 on the rating of perceived exertion (RPE). Block 2 will utilize the 5P® LOGSURF Method, termed Proprioceptive Perineal Postural Reeducation, which employs unstable positions to promote postural adjustment and continuous balance. This approach facilitates the activation of the abdominopelvic muscles, enhancing control and strengthening of the pelvic-perineal region.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Participants will engage in a 60-minute exercise session, divided into two blocks: Block 1 will comprise 10 to 12 repetitions per set, aiming to achieve a perceived exertion level of 7 to 10 on the rating of perceived exertion (RPE). Block 2 will utilize the 5P® LOGSURF Method, termed Proprioceptive Perineal Postural Reeducation, which employs unstable positions to promote postural adjustment and continuous balance. This approach facilitates the activation of the abdominopelvic muscles, enhancing control and strengthening of the pelvic-perineal region.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise control group
Description: Exercise The control group engages in specific pelvic floor exercises, which are less complex in terms of neuromuscular processing, such as Kegel's exercise. The protocol for these exercises is standardized and conducted individually, comprising 8 to 12 sessions of 20-40 minutes each, performed twice weekly.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Neuromodulation
Description: A needle with a retractable handle will be used, commonly employed in experimental research with Streitberger and Kleinhenz placebo needles. This creates the appearance of insertion without penetrating the skin and allows the needles to remain in place for the duration of the intervention.
Study: NCT06499324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTA group
Description: It consists of a blind injection of 288 IU (/144mL) of BTA (XEOMIN®) into the lateral muscles (18 injection sites, 16UI/8mL/injection site), 4 to 6 weeks before the treatment of a large anterior IH (width ≥ 10 cm) with open non absorbable mesh repair. The injection of BTA (XEOMIN®) will be done during an outpatient hospitalization, in each of the 3 lateral muscles of the abdomen on each side. To do this in the BTA group, 3 vials of 100 equivalent IU of BTA (XEOMIN® 100U), diluted to 2 IU/mL with 0.9% saline will be distributed in 3 syringes of 50 mL equipped with a 21G needle. A total of 72 mL of BTA solution (144 IU) will be injected on each side, at 3 injection points between the costal rim and iliac crest, under ultrasound control.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: It consists of a blind injection of placebo of BTA (XEOMIN® 100U matching placebo) into the lateral muscles (18 injection sites, 8mL/injection site), 4 to 6 weeks before the treatment of a large IH (width \>= 10 cm) with open non absorbable mesh repair. The injection of placebo of BTA (XEOMIN® 100U matching placebo) will be done during an outpatient hospitalization, in each of the 3 lateral muscles of the abdomen on each side. To do this in the control group, 3 vials of placebo of BTA (XEOMIN® 100U matching placebo), diluted with 0.9% saline will be distributed in 3 syringes of 50 mL equipped with a 21G needle. A total of 72 mL of placebo of BTA solution will be injected on each side, at 3 injection points between the costal rim and iliac crest, under ultrasound control.
Study: NCT06292208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBD0333
Description: This is a phase I/II, open, non-randomized, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetic (PK), immunogenicity, and preliminary efficacy of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma in dose-escalation, dose-expansion, and clinical exploration phases.
Study: NCT05999890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tapentadol Hydrochloride
Description: Intranasal administration of tapentadol was compared with intravenous paracetamol for postoperative analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Hydrochloride
Description: Intranasal administration of tapentadol was compared with intravenous paracetamol for postoperative analgesia